The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

Blood

Volumn 97, Issue 1, 2001, Pages 4-13

  Roumiantsev, Sergei ^b   De Aos, Isabel E ^b   Varticovski, Lyuba ^b   Maria, Robert L ^b   Van Etten, Richard A ^a  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P190; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ACTIVATION; IMMUNOPATHOLOGY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE HOMOLOGY;

EID: 0035166003     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.4     Document Type: Article

References (36)

1. The molecular pathogenesis of the Philadelphia-positive leukemias: Implications for diagnosis and therapy
2. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
3. BCR/ABL is not required for transformation of hematopoietic factor-dependent cells
4. Alternative forms of the bcr-abl oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
5. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
6. Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for abelson leukemia virus targets
7. Dominant negative myc blocks transformation by ABL oncogenes
8. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
9. c-Raf-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis
10. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
11. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
12. BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
13. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia
14. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation
15. Activation of PI 3-kinase in cells expressing abl oncogene variants
16. Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
17. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl
18. Association of phosphatidylinositol 3-kinase with SHC in chronic myelogenous leukemia cells
19. cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase
20. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p120BCR/ABL to the phosphatidylinositol 3′-kinase pathway
21. Phosphatidylinositol 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the p85 kD subunit
22. Phosphotidylinositol-3-OH kinase as a direct target of Ras
23. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo
24. Differential complementation of Bcr-Abl point mutants with c-myc
25. The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line
26. The BCR/ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
27. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
28. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway
29. Platelet-derived growth factor activates membrane-associated phosphatidylinositol 3-kinase and mediates its translocation from the cytosol
30. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
31. The Grb2 binding site is required for induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
32. Oncogenes and signal transduction
33. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation
34. v-Abl activates c-myc transcription through the E2F site
35. Signaling by ABL oncogenes through cyclin D1
36. Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection